Progress in the development of protein biomarkers of oesophageal and gastric cancers

Caroline Coghlin, Graeme I Murray

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Upper gastrointestinal cancers originating in the oesophagus and stomach often present late and have a very poor prognosis. Treatment options include surgery for localised disease but, increasingly, neoadjuvant chemotherapy and radiotherapy is being employed to improve outcome. There is often a variable response to neoadjuvant treatment between individual patients and side effects are relatively common. There is an urgent need for novel biomarkers of upper gastrointestinal cancer, not only to improve screening and early diagnosis of the oesophageal and gastric cancers when treatment options are potentially more effective, but also to accurately guide therapy in more advanced disease. The development of predictive biomarkers will also help to more effectively identify those patients that will benefit from targeted therapies. Although many promising results have been derived from these studies there remains a lack of validated clinically applicable biomarkers available for translation into routine clinical use. This review will provide an overview of the recent proteomic research on upper gastrointestinal cancer protein biomarker identification and validation. The challenges faced in the development of validated, clinically acceptable and accurate protein biomarkers will also be discussed, along with possible areas of future progress. This article is protected by copyright. All rights reserved.

Original languageEnglish
Pages (from-to)532-545
Number of pages14
JournalProteomics. Clinical applications
Volume10
Issue number4
Early online date19 Nov 2015
DOIs
Publication statusPublished - Apr 2016

Fingerprint

Biomarkers
Esophageal Neoplasms
Stomach Neoplasms
Gastrointestinal Neoplasms
Proteins
Neoadjuvant Therapy
Therapeutics
Tumor Biomarkers
Early Detection of Cancer
Oncology
Chemotherapy
Proteomics
Esophagus
Radiotherapy
Stomach
Surgery
Screening
Drug Therapy
Research

Keywords

  • biomarker
  • diagnosis
  • gastric cancer
  • immunohistochemistry
  • oesophageal cancer predictive
  • prognosis
  • proteomics

Cite this

Progress in the development of protein biomarkers of oesophageal and gastric cancers. / Coghlin, Caroline; Murray, Graeme I.

In: Proteomics. Clinical applications, Vol. 10, No. 4, 04.2016, p. 532-545.

Research output: Contribution to journalArticle

@article{74177e9e22f14e8ca2db4a53796daad8,
title = "Progress in the development of protein biomarkers of oesophageal and gastric cancers",
abstract = "Upper gastrointestinal cancers originating in the oesophagus and stomach often present late and have a very poor prognosis. Treatment options include surgery for localised disease but, increasingly, neoadjuvant chemotherapy and radiotherapy is being employed to improve outcome. There is often a variable response to neoadjuvant treatment between individual patients and side effects are relatively common. There is an urgent need for novel biomarkers of upper gastrointestinal cancer, not only to improve screening and early diagnosis of the oesophageal and gastric cancers when treatment options are potentially more effective, but also to accurately guide therapy in more advanced disease. The development of predictive biomarkers will also help to more effectively identify those patients that will benefit from targeted therapies. Although many promising results have been derived from these studies there remains a lack of validated clinically applicable biomarkers available for translation into routine clinical use. This review will provide an overview of the recent proteomic research on upper gastrointestinal cancer protein biomarker identification and validation. The challenges faced in the development of validated, clinically acceptable and accurate protein biomarkers will also be discussed, along with possible areas of future progress. This article is protected by copyright. All rights reserved.",
keywords = "biomarker, diagnosis, gastric cancer, immunohistochemistry, oesophageal cancer predictive, prognosis, proteomics",
author = "Caroline Coghlin and Murray, {Graeme I}",
note = "This article is protected by copyright. All rights reserved.",
year = "2016",
month = "4",
doi = "10.1002/prca.201500079",
language = "English",
volume = "10",
pages = "532--545",
journal = "Proteomics. Clinical applications",
issn = "1862-8354",
publisher = "Wiley-VCH Verlag",
number = "4",

}

TY - JOUR

T1 - Progress in the development of protein biomarkers of oesophageal and gastric cancers

AU - Coghlin, Caroline

AU - Murray, Graeme I

N1 - This article is protected by copyright. All rights reserved.

PY - 2016/4

Y1 - 2016/4

N2 - Upper gastrointestinal cancers originating in the oesophagus and stomach often present late and have a very poor prognosis. Treatment options include surgery for localised disease but, increasingly, neoadjuvant chemotherapy and radiotherapy is being employed to improve outcome. There is often a variable response to neoadjuvant treatment between individual patients and side effects are relatively common. There is an urgent need for novel biomarkers of upper gastrointestinal cancer, not only to improve screening and early diagnosis of the oesophageal and gastric cancers when treatment options are potentially more effective, but also to accurately guide therapy in more advanced disease. The development of predictive biomarkers will also help to more effectively identify those patients that will benefit from targeted therapies. Although many promising results have been derived from these studies there remains a lack of validated clinically applicable biomarkers available for translation into routine clinical use. This review will provide an overview of the recent proteomic research on upper gastrointestinal cancer protein biomarker identification and validation. The challenges faced in the development of validated, clinically acceptable and accurate protein biomarkers will also be discussed, along with possible areas of future progress. This article is protected by copyright. All rights reserved.

AB - Upper gastrointestinal cancers originating in the oesophagus and stomach often present late and have a very poor prognosis. Treatment options include surgery for localised disease but, increasingly, neoadjuvant chemotherapy and radiotherapy is being employed to improve outcome. There is often a variable response to neoadjuvant treatment between individual patients and side effects are relatively common. There is an urgent need for novel biomarkers of upper gastrointestinal cancer, not only to improve screening and early diagnosis of the oesophageal and gastric cancers when treatment options are potentially more effective, but also to accurately guide therapy in more advanced disease. The development of predictive biomarkers will also help to more effectively identify those patients that will benefit from targeted therapies. Although many promising results have been derived from these studies there remains a lack of validated clinically applicable biomarkers available for translation into routine clinical use. This review will provide an overview of the recent proteomic research on upper gastrointestinal cancer protein biomarker identification and validation. The challenges faced in the development of validated, clinically acceptable and accurate protein biomarkers will also be discussed, along with possible areas of future progress. This article is protected by copyright. All rights reserved.

KW - biomarker

KW - diagnosis

KW - gastric cancer

KW - immunohistochemistry

KW - oesophageal cancer predictive

KW - prognosis

KW - proteomics

U2 - 10.1002/prca.201500079

DO - 10.1002/prca.201500079

M3 - Article

VL - 10

SP - 532

EP - 545

JO - Proteomics. Clinical applications

JF - Proteomics. Clinical applications

SN - 1862-8354

IS - 4

ER -